New Monoterpenoid Indole Hybrids from Gelsemium elegans with Anti-Inflammatory and Osteoclast Inhibitory Activities

Chem Biodivers. 2023 Dec;20(12):e202301665. doi: 10.1002/cbdv.202301665. Epub 2023 Nov 27.

Abstract

Gelsegansymines A (1) and B (2), two new indole alkaloids along with six known analogues (3-8) were isolated from the aerial parts of Gelsemium elegans. Their structures were elucidated by means of spectroscopic techniques. Structurally, compounds 1 and 2 possessed the rare cage-like gelsedine skeleton hybrid with bicyclic monoterpenoid. The anti-inflammatory activities of isolated compounds (1-3) were tested on LPS induced RAW264.7 cells. Under the treated concentration without toxicity for cells, the cytokines levels of nitric oxide (NO), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) were evaluated by Griess method and enzyme-linked immunosorbent assay (ELISA). The results showed that compounds 1-3 exhibited anti-inflammatory activities with dose-dependent manner range from 12.5 to 50 μmol/L. Furthermore, the inhibitory activities of compounds 1 and 2 on receptor activator of NF-κB ligand (RANKL) induced osteoclast formation were tested in vitro. Compounds 1 and 2 at 5 μmol/L exhibited the significant inhibitory effect on the osteoclastogenesis induced by RANKL. This work reported the anti-inflammatory and osteoclast inhibitory activities of new monoterpenoid indole hybrids, which may inspire the further light on the related traditional application research of G. elegans.

Keywords: Anti-inflammatory activities; Gelsegansymines A and B; Gelsemium elegans; Osteoclasts.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Gelsemium* / chemistry
  • Indole Alkaloids / chemistry
  • Indole Alkaloids / pharmacology
  • Mice
  • Osteoclasts*
  • RAW 264.7 Cells
  • Tumor Necrosis Factor-alpha

Substances

  • Indole Alkaloids
  • Anti-Inflammatory Agents
  • Tumor Necrosis Factor-alpha